Skip to content

PharmaCyte Biotech, Inc.

PMCB

CIK 0001157075

← back to feed
Revenue (TTM)
$0
Q3 Mar 2026
Net Income (TTM)
−$18.08M
+9,085.0% YoY Q3 Mar 2026
EPS Diluted (TTM)
−$3.08
+277.2% YoY Q3 Mar 2026
Gross Margin
—
Q3 Mar 2026
Operating Margin
—
Q3 Mar 2026
Net Margin
—
Q3 Mar 2026
Free Cash Flow (TTM)
—
Q3 Mar 2026
Cash
$20.17M
Q3 Mar 2026
Total Debt
$2.46M
Q3 Mar 2026
Shares Outstanding
10.74M sh
Q3 Mar 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings